USFDA successfully closes inspection at Torrent Pharma Gujarat facility
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-03-06 06:27 GMT | Update On 2024-03-21 09:28 GMT
Ahmedabad: Torrent Pharma has announced that the US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (“EIR”) for the Company’s Oral-Oncology manufacturing facility situated in Bileshwarpura, Gujarat. The inspection has now been successfully closed by the USFDA.
Medical Dialogues team had earlier reported that the USFDA had concluded the Pre-Approval Inspection (PAI) inspection with 5 procedural observations at the said facility.
Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC).
Read also: Torrent Pharma reports 52 percent increase in profit after tax to Rs 443 crore for Q3
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd